OMNIlife science received FDA 510(k) clearance to market Active Spacer, a proprietary robotic tissue balancing device for use with OMNIBotics® robotic-assisted total knee replacement (TKR) technology.
Active Spacer, which has been in clinical use in Australia since 1Q17, provides management of surrounding soft tissue with real-time feedback. The OMNIBotics system for TKR is driven by OMNI’s proprietary ART™ software, and has been used to perform >16,000 procedures to date worldwide. This is an increase from the >10,000 milestone achieved by 4Q16 and >13,000 by 1Q17.
ART software is customizable to any surgical approach and allows for intra-operative adjustments, and its 3D modeling technique eliminates the need for pre-op CT scans or x-rays. The system does not require a significant capital outlay, as it is offered through a pay-per-procedure model.
Sources: OMNIlife science, Inc.; ORTHOWORLD Inc.
OMNIlife science received FDA 510(k) clearance to market Active Spacer, a proprietary robotic tissue balancing device for use with OMNIBotics® robotic-assisted total knee replacement (TKR) technology.
Active Spacer, which has been in clinical use in Australia since 1Q17, provides management of surrounding soft tissue with real-time...
OMNIlife science received FDA 510(k) clearance to market Active Spacer, a proprietary robotic tissue balancing device for use with OMNIBotics® robotic-assisted total knee replacement (TKR) technology.
Active Spacer, which has been in clinical use in Australia since 1Q17, provides management of surrounding soft tissue with real-time feedback. The OMNIBotics system for TKR is driven by OMNI’s proprietary ART™ software, and has been used to perform >16,000 procedures to date worldwide. This is an increase from the >10,000 milestone achieved by 4Q16 and >13,000 by 1Q17.
ART software is customizable to any surgical approach and allows for intra-operative adjustments, and its 3D modeling technique eliminates the need for pre-op CT scans or x-rays. The system does not require a significant capital outlay, as it is offered through a pay-per-procedure model.
Sources: OMNIlife science, Inc.; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.